Google Gemini Co-Lead Noam Shazeer Leaves for OpenAI Amid AI Talent Race 
GM and Lockheed Martin Partner to Strengthen U.S. Defense Manufacturing Capacity 
Hyundai to Acquire SoftBank’s Remaining Boston Dynamics Stake for $325 Million 
Meta Seeks Legal Shield From Child-Harm Lawsuits Amid KOSA Talks 
Qantas Unveils Wellness-Focused Nonstop Sydney-London Flights to Reduce Jet Lag 
Saudi Aramco Explores Sulphur Business Stake Sale to Raise Billions 
SpaceX Stock Slides After IPO Rally as Valuation Concerns Grow 
Microsoft Taps AWS to Support GitHub Amid AI Coding Boom 
Jio IPO Filing Nears as Reliance Targets $4 Billion Market Debut 
Frank Stronach Found Guilty of Sexual Assault and Indecent Assault in Ontario Court 
SpaceX Surpasses Amazon in Market Value as Post-IPO Rally Accelerates 
Trump Says Anthropic No Longer Seen as National Security Threat 
SK Hynix Shares Hit Record High After Shipping Next-Generation HBM4E AI Memory Samples 
Samsung Gains Interest from BYD, Google, AMD as AI Chip Demand Strains TSMC Capacity 
Kingboard Holdings Shares Surge After HK$11.77 Billion Block Trade to Expand PCB and AI Supply Chain Business 
US Raises Concerns Over Possible ASML EUV Machine Transfer to China 
BERKELEY, Calif., Jan. 07, 2016 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ:ADRO) today announced that Stephen T. Isaacs, chairman, president and chief executive officer of Aduro, was invited to present at the 34th Annual JP Morgan Healthcare Conference in San Francisco, CA on Thursday, January 14, 2016, at 10:30 am Pacific Time.
To access the live webcast and subsequent archived recording of this and the company’s other presentations, please visit Aduro's website at www.aduro.com.
About Aduro
Aduro Biotech, Inc. is a clinical-stage immunotherapy company focused on the discovery, development and commercialization of therapies that transform the treatment of challenging diseases. Aduro's technology platforms, which are designed to harness the body's natural immune system, are being investigated in cancer indications and have the potential to expand into autoimmune and infectious diseases. Aduro's LADD technology platform is based on proprietary attenuated strains of Listeria that have been engineered to express tumor-associated antigens to induce specific and targeted immune responses. Based on compelling clinical data in advanced cancers, this platform is being developed as a treatment for multiple indications, including pancreatic, lung and prostate cancers, mesothelioma and glioblastoma. Aduro's cyclic dinucleotide (CDN) platform is designed to activate the intracellular STING receptor, resulting in a potent tumor-specific immune response. Aduro’s B-select monoclonal antibody platform includes a number of immune modulating assets in research and preclinical development. Aduro is collaborating with leading global pharmaceutical companies to expand its products and technology platforms. For more information, please visit www.aduro.com.
Contact: Sylvia Wheeler SVP, Corporate Affairs 510 809 9264 Media Contact: Angela Bitting 925 202 6211 Mike Beyer Sam Brown, Inc. 312 961 2502 [email protected]
